Hainan Poly`s Generic Cisatracurium Besylate Receives Approval in the U.S.
Caplin's Generic Cisatracurium Besylate Receives Receives Approval in the U.S.
Development Of Manufacturing Technology For Three Pharmaceutical Ingredients
Piramal's Generic Cisatracurium Besylate Receives Approval in the U.S.
Enforcement Report - Week of March 3, 2021
Meitheal Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Cisatracurium Besylate Injection
Zydus Cadila has received final approval from the USFDA to market Cisatracurium Besylate Injection USP (US RLD: Nimbex) in the strength of 20 mg (base)/10 mL (2 mg/mL) multiple-dose vial.
Zydus Cadila has received the US Food and Drug Administration (FDA) approval to market cisatracurium besylate injection USP in the strength of 20 mg (base)/10 mL (2 mg/mL) multiple-dose vial.
Piramal Healthcare Generic`s Cisatracurium Besylate Reveives Approval in US
Nearly 40% of anaesthetists surveyed by the Royal College of Anaesthetists have said they are not confident that they will have sufficient supplies of anaesthetic drugs for COVID-19 patients over the next month. The survey of 2,174 anaesthetists added that 14% currently “do not have access to all the usual drugs”. This comes after the government warned on 16 April 2020 that supplies of atracurium and cisatracurium were expected to run out “over the coming days” due to increased demand from COVID-19 patients. The survey, published on 23 April 2020, said: “Departments of anaesthesia and intensive care are currently collaborating with each other and with pharmacists to ensure drugs are prioritised appropriately across the two areas.”